Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Invests €12M in France Facility

Published: Tuesday, August 12, 2014
Last Updated: Tuesday, August 12, 2014
Bookmark and Share
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.

Merck Millipore announced a €12 million investment in its Molsheim, France facility. This investment will expand Merck Millipore's Ready-To-Use (RTU) Media manufacturing capabilities, better provide security of supplies for customers in the region, and sustain the heipha/Hycon product lines including contact and settle plates (ICRplus plates) and Agar strips for RCS® systems which are used in monitoring ambient air and compressed gases. 

"We are committed to providing our customers with a reliable supply of products, including Ready-To-Use Media, which this investment in Molsheim will help to ensure," said Udit Batra, President and CEO of Merck Millipore. "Both Molsheim and heipha Eppelheim (Germany) sites will continue to support the increasing demand from our customers. This investment signifies our long-term dedication to Merck Millipore's Lab customers in this region and around the world."

This investment - which leverages Merck Millipore's core-competencies in media development and experience in media production technology - includes the extension of the manufacturing capacity space for RTU Media, a new clean room, and two additional production lines similar to those existing in Eppelheim, where RTU Media will also continue to be manufactured. In addition, current research and development laboratories across various scientific areas of expertise will be centralized to form an Innovation Center to develop solutions for future customer needs. 

The increased manufacturing capacity will serve global market demand, and will ensure sufficient capacity to support the market growth. Merck acquired the heipha/Hycon product lines in 2011 as part of its purchase of Biotest AG which expanded the division's offerings in industrial microbiology. 

Molsheim has been an important location for Merck Millipore since the facility opened in 1972. Approximately 1,030 employees are based in Molsheim. In addition to ongoing R&D activities, this site manufactures products across Merck Millipore's BioMonitoring, Lab Water, and BioPharm Process Solutions Business Fields.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
Enables accelerated process development and production of proteins/monoclonal antibodies.
Friday, September 21, 2012
Merck Millipore Announces Exclusive Agreement with Julphar Diabetes
Collaboration to offer non-animal origin, recombinant human insulin as cell culture media supplement.
Wednesday, August 08, 2012
Andrew Bulpin to Assume Leadership of Process Solutions at Merck Millipore
Bulpin appointed as head of the company's process solutions business unit.
Wednesday, May 02, 2012
Merck Millipore and CCRM Collaborate to Optimize Conditions for Large-scale Stem Cell Cultivation
Collaboration to deliver optimized methodologies for cultivation of stem cells on microcarriers in Mobius® CellReady bioreactor systems.
Tuesday, March 13, 2012
Scientific News
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Promising Drug Candidate to Treat Chronic Itch
In a new study, scientists from the Florida campus of The Scripps Research Institute (TSRI) describe a class of compounds with the potential to stop chronic itch without the adverse side effects normally associated with medicating the condition.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.
13 Ways to Stop an Unseen Force from Disrupting Weighing
Download a free Mettler Toledo paper to discover how to halt static’s negative effects before the next weigh-in.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Researchers Discover A New Mechanism of Proteins to Block HIV
Certain IFITM proteins block and inhibit cell-to-cell transmission of HIV.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Vaccination On The Horizon For Severe Viral Infection Of The Brain
Researchers from the University of Zurich and the University Hospital Zurich reveal possible new treatment methods for a rare, usually fatal brain disease.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos